These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 17849514)
1. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system. Ito K Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514 [No Abstract] [Full Text] [Related]
3. PSA screening: the bottom line. Elhilali MM CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466 [No Abstract] [Full Text] [Related]
4. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer]. Topuzov ME; Prialukhin AE; Zhivov AV; Plekhanov AIu Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832 [TBL] [Abstract][Full Text] [Related]
5. PSA and prostate cancer screening: the challenge of the new millennium. Bjartell A Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305 [No Abstract] [Full Text] [Related]
7. Is an improved PSA screening test in sight? Savage L J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529 [No Abstract] [Full Text] [Related]
8. [PSA based screening for prostatic cancer]. Johansen TE Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357 [No Abstract] [Full Text] [Related]
9. AUA issues a policy report on PSA monitoring. The American Urological Association. Scott Morey S Am Fam Physician; 2000 Aug; 62(4):883-4. PubMed ID: 10969861 [No Abstract] [Full Text] [Related]
10. [The prostate specific antigen: what can we learn from the American experience?]. Zhao XJ Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3313-5. PubMed ID: 16409833 [No Abstract] [Full Text] [Related]
11. Prostate cancer--more information and more questions. Dall'Era M; Carroll PR J Urol; 2007 May; 177(5):1607-8. PubMed ID: 17437768 [No Abstract] [Full Text] [Related]
12. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815 [TBL] [Abstract][Full Text] [Related]
13. [Based on current knowledge the introduction of the PSA screening for prostatic cancer is unethical]. Krantz I; Sachs L; Ahlberg BM; Nordin P; Nilstun T Lakartidningen; 2005 Sep 5-11; 102(36):2498-500. PubMed ID: 16196436 [No Abstract] [Full Text] [Related]
14. [No evidence that lowered PSA reference levels will help us detect those cases of prostatic cancer that will lead to morbidity and mortality]. Malmström PU Lakartidningen; 2005 Jun 27-Jul 10; 102(26-27):2005; author reply 2005. PubMed ID: 16044760 [No Abstract] [Full Text] [Related]
15. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels. Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341 [TBL] [Abstract][Full Text] [Related]
16. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality. Höltl W; Lunglmayr G Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868 [No Abstract] [Full Text] [Related]
17. [Comments on the PSA in primary health care: survey results in more "losers" than "winners"]. Bratt O Lakartidningen; 2003 Nov; 100(48):4014-5. PubMed ID: 14717100 [No Abstract] [Full Text] [Related]
18. Application of prostate-specific antigen in prostate cancer. Liang SL MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558 [No Abstract] [Full Text] [Related]
19. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group. Greiver M; Rosen N CMAJ; 2000 Mar; 162(6):789-90. PubMed ID: 10750465 [No Abstract] [Full Text] [Related]